Ajay Kumar
Since its discovery, treatment of hepatitis C virus (HCV) has undergone extensive changes. Antiviral treatments and sustained virological responses (SVR) have also improved from the early interferon monotherapy to the current all-oral regimens using direct acting antiviral (DAAs). We aimed to analyse our experience for last 4 years in treatment of hepatitis C with the currently available antivirals in terms of SVR at various time-points, new onset decompensation, hepatocellular carcinoma (HCC), mortality and side effects.
